Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States

References

• DiMichele DM. Inhibitors in Hemophilia: a primer. Hemophilia 2008;7:1-9
   Google Scholar
• Soucie JM, Miller CH, Kelly FM, et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014;20:230-7
   PubMed Web of Science ®Google Scholar
• Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011;117:6367-70
   PubMed Web of Science ®Google Scholar
• Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004;77:187-93
   PubMed Web of Science ®Google Scholar
• Brown T, Lee W, Joshi A, et al. Health-related quality of life and productivity impact in hemophilia patients with inhibitors. Hemophilia 2009;15:911-17
   PubMed Web of Science ®Google Scholar
• DeKoven M, Karkare S, Lee WC, et al. Impact of hemophilia with inhibitors on caregiver burden in the United States. Hemophilia 2014;20:822-30
   PubMed Web of Science ®Google Scholar
• Walsh CE, Sourcie JM, Miller CH. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015;90:400-5
   PubMed Web of Science ®Google Scholar
• Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among hemophilia A patients in the United States. Hemophilia 2012;18:332-8
   PubMed Web of Science ®Google Scholar
• Guh S, Grosse SD, McAlister S, et al. Health care expenditures for Medicaid-covered males with hemophilia in the United States, 2008. Hemophilia 2012;18:276-83
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Malone DC. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ 2014;17:798-802
   PubMedGoogle Scholar
• Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016;22:S126-S33
   PubMed Web of Science ®Google Scholar
• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002;28:285-90
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109:4693-7
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013;368:231-9
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35
   PubMed Web of Science ®Google Scholar
• Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46-51
   PubMed Web of Science ®Google Scholar
• Marcucci M, Mancuso ME, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A: a patient-level meta-analysis. Thromb Haemost 2015;113:958-67
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8:1256-65
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013;39:752-66
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016;374:2054-64
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, National Center for Health Statistics. Growth charts – data table of weight-for-age charts. 2001. http://www.cdc.gov/growthcharts/html_charts/wtage.htm [Accessed December 2016]
   Google Scholar
• U.S. Census Bureau, Population Division. Annual Estimates of the Resident Population: April 1, 2010 to July 1, 2015. For the United States, regions, divisions, states, and Puerto Rico Commonwealth, December 2015. https://factfinder.census.gov, [Accessed December 2016]
   Google Scholar
• Hamilton BE, Martin JA, Osterman MJK, et al. Births: final data for 2014. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics; 2015:64
   Google Scholar
• National Hemophilia Foundation. Fast facts. 2016. https://www.hemophilia.org/About-Us/Fast-Facts [Accessed December 2016]
   Google Scholar
• Alphanate [package insert]. Los Angeles, CA: Grifols Biologicals Inc; March 2015
   Google Scholar
• Advate [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; May 2015
   Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Hemophilia 2013;19:e1-e47
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Cannavo A, Garagiola I, et al. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost 2018;16:39-43
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. 2014. Healthcare cost and utilization project. http://hcupnet.ahrq.gov/HCUPnet [Accessed December 2016]
   Google Scholar
• U.S. Bureau of Labor Statistics. Consumer price index. 2018. http://data.bls.gov/cgi-bin/surveymost?cu [Accessed February 2018]
   Google Scholar
• Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004;2:861-2
   PubMed Web of Science ®Google Scholar
• Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004;2:863-5
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Palla R, et al. SIPPET: methodology, analysis and generalizability. Haemophilia 2017;3:353-61
   Web of Science ®Google Scholar
• Calvez T, Chambost H, d’Oiron R, et al. Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica 2018;103:179-89
   PubMed Web of Science ®Google Scholar
• Wali B, Halimeh S, Male C. Economic considerations on the use of recombinant vs plasmatic factor VIII in the treatment of previously untreated hemophilia A patients. Presented at the ISPOR 19th Annual Conference; October 29–November 2, 2016; Vienna Austria
   Google Scholar
• Messori A, Peyvandi F, Trippoli S, et al. High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfus 2018;16:215-220
   PubMed Web of Science ®Google Scholar
• Warren B, Wang M, Young G. Recombinant factor VIII concentrates associated with increased risk of inhibitor development in severe hemophilia a: perspectives on the results of the SIPPET trial. https://www.aap.org/en-us/Documents/SIPPET_Summary.pdf
   Google Scholar
• Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011;9:366-70
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377:809-18
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Emicizumab for hemophilia A: effectiveness and value. Draft evidence report. Boston, MA. January 26, 2018. https://icer-review.org/wp-content/uploads/2017/08/ICER_Hemophilia_A_Draft_Report_012618.pdf
   Google Scholar
• Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119:1334-44
   Web of Science ®Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5:1904-13
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with Inhibitors. N Engl J Med 2011;365:1684-92
   PubMed Web of Science ®Google Scholar
• 45. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; May 2016
   Google Scholar
• Feiba [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; November 2013
   Google Scholar
• IBM Corporation. IBM MicroMedex® 2018. http://www.micromedexsolutions.com/home/dispatch
   Google Scholar